Omeros obtains license to new antifibrinolytic agents
Omeros claims that its proprietary antifibrinolytic agents are highly selective inhibitors of plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding inhibition of Factor XIa
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.